Rebel Curd

Vice President, Practice Leader of Transfer Pricing

Ms. Rebel Curd is a vice president in Charles River Associates’ Transfer Pricing Practice and leads the global practice. She is a former partner of The Ballentine Barbera Group, which was acquired by Charles River Associates in 2006.

Ms. Curd has over two and a half decades of experience in economic analysis and business valuations from a consulting and industry background. Her areas of expertise within intercompany pricing include acquisition/integration planning, global compliance and planning, intellectual property valuation and migration, supply chain planning and optimization, and controversy. She has participated in successful intercompany pricing audits involving negotiations with the Canadian, Danish, Finnish, French, German, Italian, Japanese, Swiss, UK, and US taxing authorities. In addition to intercompany pricing analyses, Ms. Curd has experience in business valuations, economic value management, economic impact analyses, activity based costing, and econometric modeling.

Ms. Curd was selected as “Best of the Best, United States” for Transfer Pricing in Expert Guides from 2013 through 2020 as well as a Leading Transfer Pricing Practitioner in the World in Expert Guides’ 2017 Women in Business Law.  CRA was named “Transfer Pricing Firm of the Year – USA” in 2019 by Lawyer International and 2015 by Finance Monthly Tax Awards as well as “San Francisco Area Transfer Pricing Firm of the Year” in 2011 by International Tax Review.

Selected engagements

  • 01
    Supply chain reorganization for consumer products company
    CRA was engaged to redesign the supply chain of a multinational consumer product company in light of growing global tensions. Our transfer pricing team was...
    View engagement
  • 02
    Bridging US customs and transfer pricing requirements
    Rebel Curd and Robin Hart of CRA’s Transfer Pricing Practice were engaged to prepare an analysis and report that bridges income tax and customs requirements...
    View engagement
  • 03
    Cross-border biotech licensing of novel IP
    CRA provided economic analysis to a US-based biopharmaceutical company under audit by the French tax authority regarding the outbound license of novel IP from...
    View engagement